Haematology 2018

Chimeric Antigen Receptors T cells (CAR-T) in Cancer Therapy

• Adoptive cellular therapies such as tumour infiltrating lymphocytes and TCR gene-modified T-cells have demonstrated success in recent clinical trials

• Problem : Tumours often down-regulate MHC molecules and tumour specific antigens are often not known.

• Solution : Chimeric antigen receptors target cell surface proteins using antibody based recognition systems can overcome some of these problems.